UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

~~Form~~CURRENT ~~8-K~~ REPORT

~~Current~~PURSUANT ~~Report~~TO SECTION 13 OR 15(d) OF THE

~~Pursuant~~SECURITIES toEXCHANGE ~~Section~~ACT 13OF ~~or 15(d) of The Securities Exchange Act of~~ 1934

Date of Report (Date of earliest event reported): ~~October 29~~November 28, 2007

_________________________

Auriga Laboratories, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-26013 (Commission File Number)	84-1334687 (I.R.S. Employer Identification No.)
10635 Santa Monica Boulevard, Suite 120 Los Angeles, California 90025 (Address of principal executive offices) (zip code)
(310) 461-3600 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)

_________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Delaware	000-26013	84-1334687
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10635 Santa Monica Blvd. #120, Los Angeles, CA 90025

(Address of principal executive office) (zip code)

Registrant's telephone number, including area code: (310) 461-3600

N/A

(Former name or former address, if changed since last report)

_________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 1 - Registrant’s Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

On ~~October~~November 2928, 2007, weAuriga ~~entered~~Laboratories, ~~into~~Inc., a ~~Manufacturing~~Delaware ~~and~~corporation ~~Supply~~(the “Company”) entered into a License Agreement (~~the~~ “~~Manufacturing~~License Agreement ”), with ~~Mikart~~Outlook Pharmaceuticals, Inc., aan ~~Georgia~~Ohio ~~corporation~~ Corporation (“~~Mikart~~Outlook”). Under the terms of the ~~Manufacturing Agreement, Mikart was appointed to manufacture~~ ~~Acetaminophen~~License ~~650mg/Codeine 60mg (“Product”) for commercial distribution by us~~Agreement, ~~and~~ ~~Mikart~~Outlook granted ~~us an exclusive, royalty free license to market and sell~~ the ~~Product~~ inCompany the ~~United~~exclusive ~~States~~right ofin ~~America. As consideration for~~ the ~~license~~United ~~granted~~States to ~~us under the Manufacturing Agreement~~make, ~~we agreed to deliver to Mikart the aggregate sum of $100~~distribute,~~000,~~ ~~payable as follows: (i) $50~~commercialize,~~000~~ ~~payable~~market ~~upon execution of Manufacturing Agreement,~~ and ~~(ii)~~sell ~~$50,000~~a ~~payable~~new ~~within 60 days~~product ~~following~~indicated ~~our~~for ~~receipt of~~ the ~~first~~treatment ~~order~~ of ADHD (the “Product”). ~~Under~~The ~~the~~Company ~~Manufacturing~~anticipates ~~Agreement we agreed to purchase~~ Product ~~exclusively~~launch ~~from~~in ~~Mikart~~the ~~and agreed~~2nd toQuarter ~~certain~~of ~~minimum annual batch quantities~~2008.

OnIn ~~November~~consideration 5,for ~~2007,~~the weexclusive ~~issued~~license, athe ~~press~~Company ~~release~~agreed ~~announcing~~to ~~the~~make ~~Manufacturing~~payments ~~Agreement,~~to Outlook aupon ~~copy~~reaching ofor ~~which~~satisfying iscertain ~~furnished~~milestones, ~~with~~in ~~this~~accordance ~~Current Report as Exhibit~~with 99the License Agreement.1.

Section 8 - Other Events

Item 8.01 - Other Events.

A copy of the press release announcing the entry by the Company into the License Agreement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(da) ~~Exhibits~~ Financial Statements of Businesses Acquired.

Exhibit No.		Description
10.1		Manufacturing and Supply Agreement with Mikart, Inc. dated October 29, 2007
99.1		Press release dated November 5, 2007 issued by Auriga Laboratories, Inc., announcing the Manufacturing Agreement with Mikart, Inc.

Not applicable

(b)	Pro Forma Financial Information.

Not applicable

(c)	Shell Company Transactions.

Not Applicable

(d)

Exhibits.

Exhibit Number	Description



99.1	Press Release dated December 3, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~the~~Auriga ~~Registrant~~Laboratories, Inc. has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~ hereunto duly authorized.

Dated: November 2, 2007	Auriga Laboratories, Inc.
Dated: December 3, 2007	AURIGA LABORATORIES, INC.
	a Delaware corporation
	By: /s/ Frank Greico
		/s/ Philip S. Pesin
	Frank Greico
	By:	Philip S. Pesin
	Chief Financial Officer
	Its:	Chief Executive Officer

Filing Compare · AURIGA LABORATORIES, INC.